Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review

British Journal of Clinical Pharmacology
Sophie West, Praveen Bhugra

Abstract

Currently, treatment for Alzheimer's disease (AD) focuses on the cholinergic hypothesis and provides limited symptomatic effects. Research currently focuses on other factors that are thought to contribute to AD development such as tau proteins and Aβ deposits, and how modification of the associated pathology affects outcomes in patients. This systematic review summarizes and appraises the evidence for the emerging drugs affecting Aβ and tau pathology in AD. A comprehensive, systematic online database search was conducted using the databases ScienceDirect and PubMed to include original research articles. A systematic review was conducted following a minimum set of standards, as outlined by The PRISMA Group . Specific inclusion and exclusion criteria were followed and studies fitting the criteria were selected. No human trials were included in this review. In vitro and in vivo AD models were used to assess efficacy to ensure studied agents were emerging targets without large bodies of evidence. The majority of studies showed statistically significant improvement (P < 0.05) of Aβ and/or tau pathology, or cognitive effects. Many studies conducted in AD animal models have shown a reduction in Aβ peptide burden and a reduction in tau...Continue Reading

References

May 1, 1984·Journal of Neuroscience Methods·R Morris
Mar 27, 2004·Physiological Reviews·Jesus AvilaFelix Hernandez
Sep 29, 2009·Experimental Neurology·Félix HernándezJesús Avila
Jun 23, 2011·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Il-Jun KangMin-Ju Kim
May 25, 2012·Neurobiology of Aging·Rita M RamalhoCecilia M P Rodrigues
Jul 21, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Hoau-Yan WangLindsay H Burns
Aug 28, 2012·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Nae-Cherng YangTuzz-Ying Song
Nov 21, 2012·Neurobiology of Aging·Eugene O'HareRoss Jeggo
May 17, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Anna M BarronChristian J Pike
Oct 1, 2013·Neurobiology of Disease·Hope Y AgbemenyahAndre Fischer

❮ Previous
Next ❯

Citations

Feb 18, 2016·Neural Plasticity·Jaume FolchAntoni Camins
Aug 1, 2015·Neurochemical Research·Wagner Carbolin MartinsHelena Cimarosti
Feb 3, 2016·Journal of Alzheimer's Disease : JAD·Chunxia HuangGordon Tin-Chun Wong
Jan 14, 2017·Frontiers in Molecular Neuroscience·Ce Xie, Tomohiro Miyasaka
Jan 8, 2020·Biomolecules·Haroon KhanEsra Küpeli Akkol
Oct 3, 2017·Neural Regeneration Research·Josue D OrdazXiao-Ming Xu
May 28, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Amarjot Kaur GrewalMohamed M Abdel-Daim
Jul 19, 2021·Current Opinion in Chemical Biology·Fabio UrbinaSean Ekins
Aug 23, 2019·Aging and Disease·Seong Gak JeonMinho Moon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.